Allogene Q3 2024 net loss $66.3M; cash $403.4M; cash runway into 2H 2026

Allogene Therapeutics, Inc.

2024-Q3 EPS reported -$1.04 revenue$22,000

Net loss of $66.3M ($0.32/share) including $13.4M stock-based comp and $10.7M impairment; R&D $44.7M, G&A $16.3M.
Ended Q3 with $403.4M cash; maintains 2024 cash burn ~$200M and runway into 2H 2026.
Pivotal ALPHA3 cema-cel trial in 1L LBCL: ~30 sites active; enrollment completion expected 1H 2026; BLA submission targeted 2027.
ALLO-329 (CD19/CD70 dual CAR) for autoimmune disease: IND planned Q1 2025, proof-of-concept by YE 2025.
ALLO-316 for RCC received RMAT designation; Phase 1 TRAVERSE showed 50% ORR in CD70 TPS ≥50% patients.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.